Author

M. G. Joyce

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7 Microbiology· 2 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 8 Organism:human· 5 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 4 Organism:non-human primate· 3 Research Focus:cell type annotation· 2 Organism:mouse· 2

Frequent Co-Authors

R. S. Sankhala· 6 shared K. Modjarrad· 5 shared M. Choe· 5 shared W.-H. Chen· 5 shared A. Anderson· 4 shared A. Hajduczki· 4 shared J. R. Currier· 4 shared W. C. Chang· 4 shared

Activity by Year

2018-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

R. S. Sankhala

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Convergent Sequence Features of Antiviral B Cells

A. A. Abu-Shmais, M. J. Vukovich, P. T. Wasdin, Y. P. Suresh, S. A. Rush, R. A. Gillespie, R. S. Sankhala, M. Choe, M. G. Joyce, M. Kanekiyo, J. S. McLellan, I. S. Georgiev

The paper maps antibody sequences to antigen specificity across multiple viral antigens, identifying convergent sequence features in antiviral B cells.

mBio · Oct 16, 2024Peer-reviewedImmunology

Contemporary HIV-1 consensus Env with redesigned hypervariable loops promote antibody binding

H. Bai, E. Lewitus, Y. Li, V. Dussupt, B. Slike, L. Mendez-Rivera, A. Schmid, L. Wieczorek, V. Polonis, S. J. Krebs, J. A. Ake, S. Vasan, M. G. Joyce, S. Townsley, M. Rolland

The paper redesigns hypervariable loops in HIV-1 Env consensus sequences to enhance antibody binding and improve vaccine antigen design.

bioRxiv · Nov 19, 2023 · PreprintMicrobiology

A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model

S. C. Johnston, K. M. Ricks, I. Lakhal-Naouar, A. Jay, C. Subra, J. L. Raymond, H. A. D. King, F. Rossi, T. L. Clements, D. Fetterer, S. Tostenson, C. M. Cincotta, H. R. Hack, C. Kuklis, S. Soman, , A Nalca

This study evaluates a SARS-CoV-2 Spike ferritin nanoparticle vaccine in cynomolgus macaques, showing strong immunological responses and protection against infection.

bioRxiv · Mar 25, 2022Microbiology

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

M. G. Joyce, K. Modjarrad

This paper develops SARS-CoV-2 ferritin nanoparticle vaccines that elicit broad neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1, as well as variants of concern.

bioRxiv · May 9, 2021Immunology

A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells

J. M. Carmen, S. Shrivastava, Z. Lu, A. Anderson, E. B. Morrison, R. S. Sankhala, W.-H. Chen, W. C. Chang, J. Bolton, G. R. Matyas, N. L. Michael, M. G. Joyce, K. Modjarrad, J. R. Currier, E. Bergmann-Leitner, , M. Rao

This study evaluates a spike-ferritin nanoparticle vaccine with adjuvants, showing enhanced T cell responses and cross-reactivity against SARS-CoV and other coronaviruses.

bioRxiv · Apr 28, 2021 · PreprintImmunology

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

H. A. D. King, M. G. Joyce, I. Elakhal Naouar, A. Ahmed, C. Macedo Cincotta, C. Subra, K. K. Peachman, H. H. Hack, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, , L. L Jagodzinski

This study evaluates an adjuvanted SARS-CoV-2 RBD nanoparticle vaccine in macaques, showing robust immune responses and protection against viral challenge and variants.

bioRxiv · Apr 9, 2021Immunology

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

M. G. Joyce, H. A. D. King, I. Elakhal Naouar, A. Ahmed, K. K. Peachman, C. M. Cincotta, C. Subra, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, W. C. Chang, , N. Karasavva

A SARS-CoV-2 Spike ferritin nanoparticle vaccine induces broad neutralizing antibodies and protects nonhuman primates against respiratory infection and disease.

bioRxiv · Mar 24, 2021 · PreprintImmunology

A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains

B. L. Dearlove, E. Lewitus, H. Bai, Y. Li, D. B. Reeves, M. G. Joyce, P. Scott, M. Amare, S. Vasan, N. L. Michael, K. Modjarrad, M. Rolland

The paper analyzes SARS-CoV-2 sequence diversity and finds limited variation in the Spike protein, suggesting a single vaccine could be effective against current strains.

bioRxiv · Apr 27, 2020Evolutionary Biology

A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein

M. G. Joyce, R. S. Sankhala, W.-H. Chen, M. Choe, H. Bai, A. Hajduczki, L. Yan, S. L. Sterling, C. Peterson, E. C. Green, C. Smith, N. de Val, M. Amare, P. Scott, E. D. Laing, , K. Modjarrad

The paper reports the high-resolution structure of the SARS-CoV-2 Spike RBD and identifies a conserved epitope accessible in open conformations, which is targeted by cross-reactive antibodies.

bioRxiv · Mar 15, 2020 · PreprintImmunology

Design of nanoparticulate group 2 influenza hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages

K. S. Corbett, S. M. Moin, H. M. Yassine, A. Cagigi, M. Kanekiyo, S. Boyoglu-Barnum, S. I. Myers, Y. Tsybovsky, A. K. Wheatley, C. A. Schramm, R. A. Gillespie, W. Shi, L. Wang, Y. Zhang, S. F. Andrews, , J. C. Boyington

This study designs nanoparticle-based influenza HA stem antigens that activate unmutated B cell receptors of broadly neutralizing antibodies, potentially enabling cross-group immunity.

bioRxiv · Dec 17, 2018Immunology